IDH2 and myeloid neoplasm: Since the success of the Enasidenib phase 1/2 trial in myeloid malignancies and FDA approval for the indication of relapsed/refractory IDH2-mutant AML was obtained in 2017, clinical trials investigating the efficacy of mutIDH2 inhibitors, mostly Enasidenib, in various AML subpopulations have become abundant.